What is the 13F Pro Quality Score for XERS?

13F Pro ranks Xeris Biopharma Holdings, Inc. (XERS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View XERS's current score at https://13fpro.ai/research/XERS (free sign-up required for the full ranking).

Which hedge funds own the most XERS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of XERS include BlackRock,, CAPSTONE INVESTMENT ADVISORS,, D. E. Shaw & Co.,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/XERS as soon as new 13F filings post.

Where does 13F Pro source XERS data?

All Xeris Biopharma Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Xeris Biopharma Holdings, Inc. files with the SEC under CIK 1867096. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is XERS in?

Xeris Biopharma Holdings, Inc. (XERS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is XERS research updated on 13F Pro?

XERS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Xeris Biopharma Holdings, Inc.(XERS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1867096 XERS stock profile & AI dashboard →

13F Pro Quality Score

45.5/100

Rank #1,714 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

94.0/100

Profitability

31.5/100

Balance Sheet

29.3/100

Earnings Quality

30.0/100

Free Cash Flow

54.6/100

Institutional Flow

18.6/100

Revenue Scale

29.1/100

Dilution Risk

20.2/100

XERS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Xeris Biopharma Holdings, Inc. (XERS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores XERS at 45.5/100 on a 32-signal composite quality model, placing it at rank #1,714 of 2,879 stocks — the bottom half of the AI-ranked universe. XERS scores in the top quartile across revenue growth (94.0). Areas of concern include institutional flow (18.6) and revenue scale (29.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Xeris Biopharma Holdings, Inc. reports quarterly revenue of $83.1M, net income of $2.2M, an operating margin of 9.5%. Top institutional holders of XERS by reported 13-F value include BlackRock,, CAPSTONE INVESTMENT ADVISORS,, D. E. Shaw & Co.,, based on the most recent SEC filings. XERS trades on the Nasdaq exchange and files with the SEC under CIK 1867096. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate XERS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Xeris Biopharma Holdings, Inc. directly from SEC EDGAR. Xeris Biopharma Holdings, Inc.'s 13F Pro composite quality score has ranged between 8 and 81 since 2022, currently 45.5 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.

Revenue

Q1 2026

$83.1M

Net Income

Q1 2026

$2.2M

Free Cash Flow

Q1 2026

$9.9M

Operating Margin

Q1 2026

9.5%

ROIC

Q1 2026

3.4%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+78.0% YoY

$291.8MFY 2025

FY20 $20.4MFY23 $163.9MFY25 $291.8M

Net Income

+100.9% YoY

$554.0KFY 2025

FY20 $-91.1MFY23 $-62.3MFY25 $554.0K

Operating Income

+156.6% YoY

$24.9MFY 2025

FY20 $-83.5MFY23 $-44.0MFY25 $24.9M

EPS (Diluted)

+100.0% YoY

$0.00FY 2025

FY20 —FY23 $-0.45FY25 $0.00

Total Assets

+18.9% YoY

$383.5MFY 2025

FY20 $159.2MFY23 $322.6MFY25 $383.5M

Total Debt

+15.4% YoY

$220.3MFY 2025

FY20 $87.0MFY23 $190.9MFY25 $220.3M

Op. Cash Flow

+160.9% YoY

$28.6MFY 2025

FY20 $-80.6MFY23 $-47.0MFY25 $28.6M

Metric	FY 2025	FY 2023	FY 2020
Revenue	$291.8M +78.0%	$163.9M +702.1%	$20.4M
Net Income	$554.0K +100.9%	$-62.3M +31.7%	$-91.1M
Operating Income	$24.9M +156.6%	$-44.0M +47.3%	$-83.5M
EPS (Diluted)	$0.00 +100.0%	$-0.45	—
Total Assets	$383.5M +18.9%	$322.6M +102.7%	$159.2M
Total Debt	$220.3M +15.4%	$190.9M +119.4%	$87.0M
Operating Cash Flow	$28.6M +160.9%	$-47.0M +41.6%	$-80.6M

AI Insight: XERS Financial Trends

Xeris reached GAAP profitability in Q4 2025 for the first time in the visible data set, with revenue up 59% from Q3 2024 to Q1 2026.

• Revenue grew from $54M in Q3 2024 to $86M in Q4 2025, a 59% increase over five quarters, with Q1 2026 holding at $83M.

• Operating income turned decisively positive, rising from -$13M in Q3 2024 to $17M in Q4 2025 and $8M in Q1 2026.

• Operating cash flow swung from -$8M in Q3 2024 to $20M in Q4 2025, signaling improving cash generation.

• Equity turned positive at $14M in Q4 2025 and held at $13M in Q1 2026, up from -$35M in Q1 2025.

⚠ Total debt remains elevated at $221M in Q1 2026; sustained free cash flow needed to meaningfully reduce leverage.

⚠ Net income and operating CF both pulled back in Q1 2026 versus Q4 2025 — watch whether seasonal softness persists.

AI Insight: XERS Ratio Trends

Xeris has turned the corner from deep losses to consistent operating profitability, with ROIC surging from -25.4% in Q3 2024 to 28.7% in Q4 2025.

• Operating margin swung from -23.8% in Q3 2024 to a peak of 19.6% in Q4 2025, signaling a decisive shift to sustainable profitability.

• ROIC recovered sharply from -25.4% in Q3 2024 to 28.7% in Q4 2025, with TTM ROIC settling at 15.3%.

• Net profit margin turned positive in Q3 2025 (0.8%) and jumped to 12.9% in Q4 2025, ending two quarters of losses.

⚠ Q1 2026 margins pulled back — OpMargin fell from 19.6% to 9.5% and ROIC from 28.7% to 13.5% — watch for seasonality vs. structural reversal.

⚠ D/E remains elevated at 17.00 in Q1 2026, up from 16.10 in Q4 2025; leverage constrains financial flexibility if profitability slips.

⚠ TTM ROE of 92.3% versus Q1 2026 quarterly ROE of 68.7% may reflect denominator effects; equity base quality warrants monitoring.

Get alerted when XERS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Xeris Biopharma Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of XERS

BlackRock, Inc.
$75.1M12,945,785 sh
CAPSTONE INVESTMENT ADVISORS, LLC
$47.2M23,074,000 sh
D. E. Shaw & Co., Inc.
$45.2M7,788,811 sh
STATE STREET CORP
$27.0M4,658,174 sh
GEODE CAPITAL MANAGEMENT, LLC
$24.9M4,290,629 sh
Qube Research & Technologies Ltd
$23.9M4,114,425 sh
Polar Asset Management Partners Inc.
$21.5M10,500,000 sh
Rosalind Advisors, Inc.
$18.7M3,231,700 sh
Nuveen, LLC
$16.9M2,916,598 sh
MORGAN STANLEY
$14.9M2,572,654 sh

Fund	Value	Shares
BlackRock, Inc.	$75.1M	12,945,785
CAPSTONE INVESTMENT ADVISORS, LLC	$47.2M	23,074,000
D. E. Shaw & Co., Inc.	$45.2M	7,788,811
STATE STREET CORP	$27.0M	4,658,174
GEODE CAPITAL MANAGEMENT, LLC	$24.9M	4,290,629
Qube Research & Technologies Ltd	$23.9M	4,114,425
Polar Asset Management Partners Inc.	$21.5M	10,500,000
Rosalind Advisors, Inc.	$18.7M	3,231,700
Nuveen, LLC	$16.9M	2,916,598
MORGAN STANLEY	$14.9M	2,572,654

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put XERS on your watchlist

Track score changes the day Xeris Biopharma Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is XERS a good stock to buy?

13F Pro's AI-powered analysis of Xeris Biopharma Holdings, Inc. (XERS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for XERS are available on the XERS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own XERS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling XERS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Xeris Biopharma Holdings, Inc.'s investment landscape.